Jacobio Pharmaceuticals Group, a Chinese clinical-stage pharmaceutical firm focusing on oncology therapies, has raised about HK$1.35 billion ($174.1 million) in an initial public offering (IPO) on the main board of the Stock Exchange of Hong Kong on Monday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
